PDF Archive search engine
Last database update: 17 February at 11:24 - Around 76000 files indexed.
35RC16_9734_eNERGY NOTE D’INFORMATION Etude randomisée de phase III comparant l’association du nivolumab et de l’ipilimumab versus un doublet à base de carboplatine dans le traitement de première ligne du CBNPC avancé chez des patients PS 2 ou de plus de 70 ans eNERGY N° EudraCT :
https://www.pdf-archive.com/2017/11/14/energy-noteinfoconsentement-v2-0-2017-11-06/
14/11/2017 www.pdf-archive.com
ENERGY Trial Code Sponsor 35RC16_9734 / GFPC 08-2015 / BMS CA209-449 ENERGY Randomised phase III study testing nivolumab and ipilimumab versus a carboplatin based doublet in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer.
https://www.pdf-archive.com/2017/11/14/energy-protocole-signe-v2-0-2017-11-06/
14/11/2017 www.pdf-archive.com
It is important to highlight that 2016 will be a pivotal year for Heat Biologics, as the Company will report randomized Phase II data in bladder and lung cancer, and results from the DURGA trial combining HS-110 with Keytruda (nivolumab).
https://www.pdf-archive.com/2016/08/11/lsc-htbx-note-02022016/
11/08/2016 www.pdf-archive.com
Keith Kerr (UK) Poster Oral Presentations Matthew Callister (UK) and Cindy Billingham (UK) Introduction - 7 minutes + 4 minutes discussion per speaker Psychological impact of low-dose CT screening in a ‘real world’ demonstration lung cancer screening pilot Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX) Modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients PD-L1 expression in resected non-small cell lung cancer;
https://www.pdf-archive.com/2018/12/10/btog-2019-programme-v7-draft/
10/12/2018 www.pdf-archive.com